Aimmune Therapeutics, Inc. (AIMT)
(Delayed Data from NSDQ)
$19.72 USD
-0.07 (-0.35%)
Updated May 3, 2019 04:00 PM ET
After-Market: $19.75 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[AIMT]
Reports for Purchase
Showing records 1 - 20 ( 231 total )
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Nestle''s Acquisition of Aimmune Could Be Good For Shareholders - Patients
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Industry: Medical - Biomedical and Genetics
Downgrading to NEUTRAL: Societes des Produits Nestle S.A to Acquire AIMT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
QoL Data Shows Need for PALFORZIA in Europe Ahead of 4Q20 Approval
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Q2; Uptick in PALFORZIA- Sales Expected in H2; Next, MAA Decision in Q4
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
2Q20 Earnings - PALFORZIA''s EU Approval - Multiple Data Updates Ahead
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Industry: Medical - Biomedical and Genetics
Palforzia Launch Sails Into the Perfect Storm, As Quarter Returns Zero Net Product Sales
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
EAACI: Long-Term Data Reaffirms PALFORZIA Positive Benefit-Risk Profile
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Long-Term Immunomodulation Insights Set Stage for Palforzia Commercial Story
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
Multiple Supportive Presentations for Palforzia to Be Presented at EAACI
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Industry: Medical - Biomedical and Genetics
Multiple Supportive Presentation for Palforzia to Be Presented at EAACI
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Industry: Medical - Biomedical and Genetics
Q1-Cash Rich; We Anticipate PALFORZIA? Re-Acceleration in H2
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Pandemic Impact on Palforzia Launch, Traction Yet to Be Seen; Reducing to $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A